×
0 0.00534759358288778 0.0427807486631016 0.0427807486631016 0 -0.016042780748663 0 0.00962566844919804
Stock impact report

Hookipa Pharma jumps 40% after FDA approval of clinical tests [MarketWatch]

REDHOOK ALE BREWERY INC (HOOK)  More Company Research Source: MarketWatch
PDF Hookipa Pharma jumps 40% after FDA approval of clinical tests Hookipa Pharma Inc. HOOK, -2.34% shares jumped 40% in late trading Thursday after the company announced that the Food and Drug Administration approved a study of the company's immunotherapy approach to certain cancers. Hookipa had asked the FDA for clearance on a phase 1/2 study of HB-201, and with its approval will now start its first clinical trial in immuno-oncology, the company said. "With the FDA's clearance of our IND application we have achieved an important milestone advancing HB-201 into clinical development," Chief Executive Joern Aldag said in the announcement. Hookipa, which went public in April , closed Thursday at $6.68, but shares neared $9.50 in after-hours trading following the announcement. [Read more]
Impact snapshot Event time: HOOK
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
HOOK alerts
from News Quantified
Opt-in for
HOOK alerts

from News Quantified
Opt-in for
HOOK alerts

from News Quantified